Profil
John Archibald Troup formerly worked at Medisyn Technologies, Inc., as Director from 2007 to 2018, VitalMedix, Inc., as Director & Business Consultant in 2009, Intelgenx Corp., as Director, IntelGenx Technologies Corp., as Independent Director from 2011 to 2018, The Twinwest Political Action Committee, as Director, Upsher-Smith Laboratories LLC, as President & Chief Operating Officer in 2003, Schwarz Pharma, Inc., as President in 1995, and Schwarz Pharma Ltd., as President & Chief Operating Officer.
Anciens postes connus de John Archibald Troup
| Sociétés | Poste | Fin |
|---|---|---|
| INTELGENX TECHNOLOGIES CORP. | Director/Board Member | 26/01/2018 |
Medisyn Technologies, Inc.
 Medisyn Technologies, Inc. Pharmaceuticals: MajorHealth Technology Medisyn Technologies, Inc. develops novel pharmaceuticals, nutraceuticals, and animal health products. The firm engages in the development of pre-qualified proprietary drug compounds. Its Forward Engineering platform is focused on predicting the behavior of molecules from topology. The company was founded in 1999 and is headquartered in Minnetonka, MN. | Director/Board Member | 26/01/2018 |
Intelgenx Corp.
 Intelgenx Corp. Pharmaceuticals: MajorHealth Technology Intelgenx Corp. develops oral-controlled release pharmaceutical products. The firm offers pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. The company was founded in 2003 and is headquartered in Saint-Laurent, Canada. | Director/Board Member | 26/01/2018 |
| The Twinwest Political Action Committee | Director/Board Member | 26/01/2018 |
VitalMedix, Inc.
 VitalMedix, Inc. BiotechnologyHealth Technology VitalMedix, Inc., is a Minneapolis-based, development-stage company that has developed a proprietary, rapidly deployable formulation called Tamiasyn that will potentially allow the human body to endure severe blood loss for an extended period of time and also inhibit human organ damage during the resuscitation process. VitalMedix intends to market Tamiasyn in combination with a hemorrhagic shock treatment system named O2Rescue. It is hoped that this system will offer first responders, trauma center surgeons and military medics a simple, safe and reliable product for preventing serious organ damage and death among victims of severe blood loss. It is believed that Tamiasyn might also have potential applications during invasive surgery and organ preservation, and in cases of stroke. Since 2005, the research conducted by VitalMedix has been funded by the Defense Advanced Research Projects Agency (DARPA). Much of this research has been conducted at the University of Minnesota, which is a shareholder in VitalMedix, Inc. The company now holds an exclusive, global license from the University of Minnesota for Tamiasyn. In order for human trials to begin, the Company will need to have an approved Investigational New Drug [IND] application on file with FDA. The IND provides a compilation of all R&D conducted to date including formulation development, animal pharmacology and toxicology, and supportive literature. The IND must also include a plan for intended additional animal studies and clinical trials. Typically, the time to market for a viable drug candidate is 8-10 years. However, manufacturers can request 'fast track' designation for their product and indication for use if the product offers potential as a life-saving technology superior to current therapies. If designated, FDA will work closely with the manufacturer and provide expedited review and approval times if appropriate. VitalMedix, Inc. intends to request fast track status for Tamiasyn in hemorrhagic shock. | Director/Board Member | 01/12/2009 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INTELGENX TECHNOLOGIES CORP. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Medisyn Technologies, Inc.
Medisyn Technologies, Inc. Pharmaceuticals: MajorHealth Technology Medisyn Technologies, Inc. develops novel pharmaceuticals, nutraceuticals, and animal health products. The firm engages in the development of pre-qualified proprietary drug compounds. Its Forward Engineering platform is focused on predicting the behavior of molecules from topology. The company was founded in 1999 and is headquartered in Minnetonka, MN. | Health Technology |
VitalMedix, Inc.
VitalMedix, Inc. BiotechnologyHealth Technology VitalMedix, Inc., is a Minneapolis-based, development-stage company that has developed a proprietary, rapidly deployable formulation called Tamiasyn that will potentially allow the human body to endure severe blood loss for an extended period of time and also inhibit human organ damage during the resuscitation process. VitalMedix intends to market Tamiasyn in combination with a hemorrhagic shock treatment system named O2Rescue. It is hoped that this system will offer first responders, trauma center surgeons and military medics a simple, safe and reliable product for preventing serious organ damage and death among victims of severe blood loss. It is believed that Tamiasyn might also have potential applications during invasive surgery and organ preservation, and in cases of stroke. Since 2005, the research conducted by VitalMedix has been funded by the Defense Advanced Research Projects Agency (DARPA). Much of this research has been conducted at the University of Minnesota, which is a shareholder in VitalMedix, Inc. The company now holds an exclusive, global license from the University of Minnesota for Tamiasyn. In order for human trials to begin, the Company will need to have an approved Investigational New Drug [IND] application on file with FDA. The IND provides a compilation of all R&D conducted to date including formulation development, animal pharmacology and toxicology, and supportive literature. The IND must also include a plan for intended additional animal studies and clinical trials. Typically, the time to market for a viable drug candidate is 8-10 years. However, manufacturers can request 'fast track' designation for their product and indication for use if the product offers potential as a life-saving technology superior to current therapies. If designated, FDA will work closely with the manufacturer and provide expedited review and approval times if appropriate. VitalMedix, Inc. intends to request fast track status for Tamiasyn in hemorrhagic shock. | Health Technology |
Upsher-Smith Laboratories LLC
 Upsher-Smith Laboratories LLC Pharmaceuticals: MajorHealth Technology Upsher-Smith Laboratories, Inc. manufactures generic pharmaceuticals. It serves the pharmacists, physicians, and patients. The firm offers manufacturing, distribution, sales, and marketing services. The company was founded by Frederick Alfred Upsher Smith in 1919 and is headquartered in Maple Grove, MN. | Health Technology |
Schwarz Pharma, Inc.
 Schwarz Pharma, Inc. Pharmaceuticals: MajorHealth Technology SCHWARZ PHARMA, Inc. develops and manufactures pharmaceutical products. The company's products include Codimal, Colyte, Edex, Kutrase, Levatol, Robaxin, and Verelan. It was founded in 2003 and is headquartered in Mequon, WI. | Health Technology |
Intelgenx Corp.
Intelgenx Corp. Pharmaceuticals: MajorHealth Technology Intelgenx Corp. develops oral-controlled release pharmaceutical products. The firm offers pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. The company was founded in 2003 and is headquartered in Saint-Laurent, Canada. | Health Technology |
Schwarz Pharma Ltd.
 Schwarz Pharma Ltd. Pharmaceuticals: MajorHealth Technology Schwarz Pharma Ltd. is a British company that manufactures pharmaceutical products. | Health Technology |
| The Twinwest Political Action Committee |
